Literature DB >> 3410065

An epidemiological survey of Raynaud's phenomenon.

J C de Trafford1, K Lafferty, C E Potter, V C Roberts, L T Cotton.   

Abstract

A questionnaire was sent to 1000 patients with Raynaud's phenomenon (RP) and an equal number of controls in order to accumulate one of the largest patient data banks currently available. Five-hundred and seventy-one correctly completed paired returns were processed so as to investigate the association between Raynaud's phenomenon and other factors suspected of influencing the condition. The involvement of female sex hormones in RP was indicated by the predominance of women (93%), a 6% (P less than 0.02) higher incidence of infertility and the influence of menstruation (15%), the menopause (73%) and pregnancy (53%) on symptoms. Patients with scleroderma had a 5% higher incidence of stillbirths. A familial predisposition for RP was noted dependent on age at onset of symptoms (age less than 30, 14% greater than 30, 4.9%). The Raynaud's group overall had a significantly higher percentage who had been treated for migraine (7% higher P less than 0.01), angina (3% higher P less than 0.05) and duodenal ulcer (3% higher P less than 0.001). Of the respondents who had undergone sympathectomy (n = 140, 24.5% of the total), 18.6% claimed lasting benefit and 66.4% claimed no benefit after one year. The mean age at sympathectomy was 38.6 years (S.D. +/- 13 range 14-78) with a mean age of start of symptoms of 29.2 years (S.D. +/- 14.7, range 0-70). There was no significant difference between the effects of sympathectomy on those patients with and those without associated conditions.

Entities:  

Mesh:

Year:  1988        PMID: 3410065     DOI: 10.1016/s0950-821x(88)80070-7

Source DB:  PubMed          Journal:  Eur J Vasc Surg        ISSN: 0950-821X


  9 in total

Review 1.  Raynaud's phenomenon: epidemiology and risk factors.

Authors:  Liana Fraenkel
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

2.  Prevalence of Raynaud's phenomenon in a healthy Greek population.

Authors:  P V Voulgari; Y Alamanos; D Papazisi; K Christou; C Papanikolaou; A A Drosos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

3.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

Review 4.  Thoracic sympathectomy: a review of current indications.

Authors:  Moshe Hashmonai; Alan E P Cameron; Peter B Licht; Chris Hensman; Christoph H Schick
Journal:  Surg Endosc       Date:  2015-06-27       Impact factor: 4.584

Review 5.  [Evidence-based therapy of Raynaud's syndrome].

Authors:  M Distler; J Distler; A Ciurea; D Kyburz; U Müller-Ladner; K Reich; O Distler
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

6.  Prevalence of Raynaud's phenomenon in young Greek males.

Authors:  Vassilios Tzilalis; Nikolaos Panagiotopoulos; George Papatheodorou; Efstathios Rallis; Dimitrios Kassimos
Journal:  Clin Rheumatol       Date:  2010-12-01       Impact factor: 2.980

7.  Prevalence of symptoms of Raynaud's phenomenon in general practice.

Authors:  A Silman; S Holligan; P Brennan; P Maddison
Journal:  BMJ       Date:  1990-09-22

8.  Management of Raynaud's Phenomenon in the Patient with Connective Tissue Disease.

Authors:  Soumya Chatterjee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-04

Review 9.  Pharmacotherapy of Raynaud's phenomenon.

Authors:  J J Belch; M Ho
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.